EU MDR, FDA, HSA — How Orbid AI Handles Multi-Regime Compliance in One Tender

The Multi-Regime Compliance Challenge

Medical device companies that compete in international tenders face a regulatory reality that domestic manufacturers never encounter: a single tender can reference multiple regulatory regimes simultaneously. A hospital group in Singapore might require HSA registration, reference EU MDR essential requirements for benchmarking, and demand FDA-style predicate device analysis as part of the clinical evaluation. A GPA-aligned tender from a Middle Eastern procurement authority might require certificates recognized under EU MDR, testing reports aligned with FDA guidance documents, and local registration through a national authority that has its own unique requirements.

For Chinese OEM medical device exporters, the multi-regime challenge is compounded by the need to transform NMPA-based regulatory evidence into formats recognized by each target authority. This is not translation — it is regulatory evidence transformation. And doing it manually for every tender is the single biggest bottleneck preventing Chinese medical device companies from scaling their international business. Orbid AI's Intel module was built specifically to solve this problem.

The 14 Regulatory Regimes in Intel's Knowledge Graph

Orbid AI's Intel module maintains a compliance knowledge graph that maps the following 14 regulatory regimes and their interrelationships:

• EU MDR (2017/745) — The European regulation covering general medical devices, including classification rules, essential requirements, and conformity assessment pathways through Notified Bodies.

• FDA 510(k) and PMA — United States pathways for market clearance (510(k) substantial equivalence) and approval (Pre-Market Approval for Class III devices).

• China NMPA — The National Medical Products Administration registration system, including Class I filing, Class II and III registration, and the Chinese national standards that underpin product testing.

• Japan PMDA — The Pharmaceuticals and Medical Devices Agency approval pathway, including Shonin (approval) and Todokede (notification) categories.

• South Korea MFDS — The Ministry of Food and Drug Safety device classification and registration system.

• Australia TGA — The Therapeutic Goods Administration registration process, including the Australian Register of Therapeutic Goods (ARTG) listing requirements.

• Brazil ANVISA — The Brazilian Health Regulatory Agency registration process, including GMP certification requirements for manufacturing facilities.

• Health Sciences Authority Singapore (HSA) — The HSA medical device registration framework, which includes ASEAN harmonization elements.

• Health Canada — The Medical Devices Regulations under the Food and Drugs Act, including device classification and licensing requirements.

• MHRA United Kingdom — Post-Brexit UK regulatory framework, now separate from EU MDR with its own conformity assessment requirements.

• Saudi FDA (SFDA) — The Saudi Food and Drug Authority registration system for medical devices entering the Saudi market.

• India CDSCO — The Central Drugs Standard Control Organisation medical device regulatory framework.

• WHO Prequalification — The WHO prequalification pathway relevant for devices procured through UN agencies and global health organizations.

• WTO GPA Framework — The World Trade Organization Government Procurement Agreement, which governs procurement procedures for signatory nations and references multiple national regulatory standards.

How Intel Maps Cross-Regime Equivalences

The core of Intel's value is not simply listing what each regime requires — it is mapping the relationships between regimes. These relationships fall into four categories:

Mutual Recognition Agreements (MRAs): Some regulatory authorities formally recognize each other's testing and certification processes. For example, the EU has MRAs with certain countries that allow conformity assessment results from one jurisdiction to be accepted in another. Intel tracks which MRAs are active, which device categories they cover, and which testing laboratories are recognized under each agreement.

Standard Equivalences: Many national standards are based on the same international standards (ISO, IEC) but with national deviations. Intel maps these equivalences at the clause level. For example, the Chinese national standard GB 9706.1 is based on IEC 60601-1, but with specific deviations in certain clauses. Intel knows which clauses are equivalent and which require additional testing to bridge the gap between NMPA and EU MDR compliance evidence.

Predicate Relationships: In the FDA 510(k) pathway, manufacturers must demonstrate substantial equivalence to a legally marketed predicate device. Intel maintains predicate device databases and can identify potential predicates for Chinese OEM devices entering the US market, streamlining the 510(k) submission process and ensuring tender responses accurately represent the regulatory pathway.

Gap Analysis: When no equivalence or recognition exists between two regimes, Intel identifies the specific gaps and provides remediation guidance. For a Chinese manufacturer with NMPA registration seeking to bid on a tender requiring EU MDR compliance, Intel generates a gap analysis showing exactly which additional testing, documentation, and certification steps are needed.

Certificate Expiry Tracking Across Regimes

One of the most operationally critical features of Intel is automated certificate expiry tracking across all 14 regimes. Medical device certificates have different validity periods in different jurisdictions: EU MDR certificates are typically valid for 5 years, NMPA registrations for 5 years but with annual reporting requirements, FDA 510(k) clearances do not expire but require compliance with ongoing requirements, and HSA registrations require periodic renewal.

Intel tracks expiry dates for every certificate in Arsenal and generates alerts at multiple thresholds: 6 months before expiry, 3 months before expiry, and immediately upon expiry. More importantly, Intel cross-references certificate expiry dates against active tender timelines. If a tender evaluation period extends beyond a certificate's expiry date, Intel flags this in the tender response so the team can either accelerate the renewal or address the timing gap in their submission.

Companies managing portfolios of 15 or more product configurations across multiple markets may have hundreds of certificates with different expiry dates. Manual tracking of these certificates is where many compliance errors originate — the certificate exists and has been renewed, but the tender team references the old certificate number because they are working from outdated records. Intel eliminates this error category entirely by maintaining a single source of truth for all certificate data across all regimes.

Chinese OEM Evidence Transformation

For Orbid AI's primary market — Chinese OEM medical device exporters — the most valuable capability of Intel is evidence transformation. Chinese manufacturers hold NMPA registrations backed by extensive testing at Chinese laboratories against Chinese national standards. This evidence is rigorous and substantive, but it is not immediately usable in international tender responses for several reasons.

First, the testing standards are national adaptations of international standards, with deviations that must be identified and addressed. Intel maps these deviations automatically, identifying which test results from Chinese laboratories can be cited directly and which require supplementary testing to meet international requirements.

Second, the certificate formats and documentation structures differ from what international procurement authorities expect. Intel transforms NMPA-based evidence into presentation formats that align with each target authority's expectations. For an EU MDR-referenced tender, Intel restructures the evidence to align with Annex II and III requirements. For an FDA-referenced tender, it aligns with 510(k) submission format conventions.

Third, testing laboratory recognition varies by regime. A test report from a Chinese laboratory accredited by CNAS may be recognized by some international authorities but not others. Intel maintains laboratory recognition databases and flags when test reports need to be supplemented by testing at internationally recognized laboratories.

The founding team at Orbid built this capability because they lived the problem at Comen Medical, an $85 million medical device company. Their NMPA-registered products — patient monitors, ventilators, infusion pumps — had been tested rigorously and met high safety and performance standards. But their international win rate was 19 percent because their tender responses could not present this evidence in ways that international procurement evaluators could interpret and trust. After implementing Intel's evidence transformation, their win rate doubled to 38 percent.

Multi-Regime Compliance in a Single Tender Response

When Operator processes a tender that references multiple regulatory regimes, Intel provides a unified compliance view. Instead of treating each regime as a separate compliance exercise, Intel identifies overlaps — requirements satisfied by a single certificate or test report — and presents them efficiently. This reduces redundancy in the response while ensuring complete coverage.

For example, a tender requiring both EU MDR and HSA compliance for a patient monitoring system might have 40 overlapping requirements (standards referenced by both authorities), 15 EU MDR-specific requirements, and 8 HSA-specific requirements. Intel maps these relationships so that Operator can draft a response that cites the same test report once for overlapping requirements rather than duplicating evidence. This makes the response cleaner, easier for evaluators to review, and more likely to score well on completeness criteria.

The complete multi-regime compliance verification runs as part of Operator's 46-second pipeline. For companies managing over 30 tenders per quarter across multiple markets, this automated multi-regime handling is what makes high-volume international tender response feasible. Without it, each regime requires a separate compliance review cycle, multiplying the work by the number of regimes referenced.

If your company is navigating multi-regime compliance challenges in international tenders, contact Orbid AI to see how Intel maps your specific regulatory portfolio across target markets.